Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR8816] to p53R2 (HRP)
- Suitable for: WB
- Knockout validated
- Reacts with: Human
- Conjugation: HRP
Product nameAnti-p53R2 antibody [EPR8816] (HRP)
See all p53R2 primary antibodies
DescriptionRabbit monoclonal [EPR8816] to p53R2 (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human p53R2 (N terminal).
Database link: Q7LG56
- WB: SW480 and wildtype HAP1 whole cell lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 1% BSA, PBS, 30% Glycerol
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab206095 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa).|
FunctionPlays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage.
Tissue specificityWidely expressed at a high level in skeletal muscle and at a weak level in thymus. Expressed in epithelial dysplasias and squamous cell carcinoma.
PathwayGenetic information processing; DNA replication.
Involvement in diseaseDefects in RRM2B are the cause of mitochondrial DNA depletion syndrome type 8A (MTDPS8A) [MIM:612075]. A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.
Defects in RRM2B are the cause of mitochondrial DNA depletion syndrome type 8B (MTDPS8B) [MIM:612075]. A disease due to mitochondrial dysfunction and characterized by ophthalmoplegia, ptosis, gastrointestinal dysmotility, cachexia, peripheral neuropathy.
Defects in RRM2B are the cause of progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 5 (PEOA5) [MIM:613077]. A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.
Sequence similaritiesBelongs to the ribonucleoside diphosphate reductase small chain family.
Cellular localizationCytoplasm. Nucleus. Translocates from cytoplasm to nucleus in response to DNA damage.
- Information by UniProt
- DKFZp686M05248 antibody
- MGC102856 antibody
- MGC42116 antibody
All lanes : Anti-p53R2 antibody [EPR8816] (HRP) (ab206095) at 1/1000 dilution
Lane 1 : SW480 (Human colon adenocarcinoma cell line) Whole Cell Lysate at 10 µg
Lane 2 : Wild-type HAP1 cell lysate at 20 µg
Lane 3 : p53R2 knockout HAP1 cell lysate at 20 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 40 kDa
Observed band size: 40 kDa
Exposure time: 8 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab206095 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab206095 has not yet been referenced specifically in any publications.